LQDA Liquidia Corporation

Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022

Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022

MORRISVILLE, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

The live call may be accessed by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and entering the conference code: 7467713. A webcast of the call will be available and archived for 30 days on Liquidia’s website at .

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder, an investigational, inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection. For more information, please visit .

Contact Information for Media & Investors

Jason Adair

Senior Vice President, Corporate Development and Strategy

919.328.4400



EN
01/11/2022

Underlying

LQDALiquidia Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Liquidia Corporation

 PRESS RELEASE
Free
LQDA Liquidia Corpor...

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powde...

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) FDA’s approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILDYUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effortDemonstrated tolerability and titratability in the pivotal INSPIRE studyLiquidia will host a webcast Tuesday, May 27, 2025 at 8:30 a.m. ET to provide an update on...

May 23, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation Provides Update on Litigation Filed by United The...

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA‘782 patent claims same general subject matter as UTHR’s invalidated ‘793 patentDoes not impact FDA’s ability to take final action on NDA for YUTREPIA on PDUFA goal date of May 24, 2025 MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company develop...

May 12, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation Reports First Quarter 2025 Financial Results and ...

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in patients with PH-ILDFurther strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare RoyaltyCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a...

May 8, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Present at BofA Securities 2025 Health Care Co...

Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced  that the company’s Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET ...

May 6, 2025 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

District Court Dismisses Dispute Filed by United Therapeutics Against ...

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District Court for the District of Columbia (District Co...

May 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch